OVID - Ovid Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.3700
-0.0200 (-0.84%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.3900
Open2.3800
Bid0.0000 x 1800
Ask0.0000 x 900
Day's Range2.3300 - 2.4280
52 Week Range1.5300 - 6.6080
Volume217,729
Avg. Volume490,476
Market Cap94.693M
Beta (3Y Monthly)2.46
PE Ratio (TTM)N/A
EPS (TTM)-1.7820
Earnings DateAug 7, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.33
Trade prices are not sourced from all markets
  • Will Ovid Therapeutics Continue to Surge Higher?
    Zacks

    Will Ovid Therapeutics Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor Ovid Therapeutics.

  • Jeremy Levin Is The Chairman & CEO of Ovid Therapeutics Inc. (NASDAQ:OVID) And They Just Spent US$150k On Shares
    Simply Wall St.

    Jeremy Levin Is The Chairman & CEO of Ovid Therapeutics Inc. (NASDAQ:OVID) And They Just Spent US$150k On Shares

    Investors who take an interest in Ovid Therapeutics Inc. (NASDAQ:OVID) should definitely note that the Chairman & CEO...

  • Barrons.com

    Ovid Therapeutics, Sunrun, Pure Cycle, and Other 13D Filings

    TLS Advisors disclosed on Oct. 7 that it held 3,466,394 shares of the small-cap biopharmaceutical company after the purchase of 1,220 shares on Sept. 3 at prices of $1.73 to $1.75 apiece and the sale of 17,507 shares from Sept. 10 through Oct. 4 at per share prices of $2.25 to $2.76. TLS now owns a 7.3% interest in Ovid following its purchases. TLS Advisors noted that it has acquired Ovid “for investment purposes” and further revealed that the managing director of TLS, Mark Feldberg, has spoken to Ovid and “expects to continue to speak with management of [Ovid] to discuss enhancing shareholder value,” among other topics.

  • Globenewswire Test

    Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock

    NEW YORK, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases, today announced the pricing of two concurrent but separate underwritten public offerings (together, the “Offerings”) of (i) 9,000,000 shares of its common stock and (ii) 4,000 shares of its non-voting Series A Convertible Preferred Stock (the “Series A preferred stock”). The public offering price of each share of common stock is $2.50 and the public offering price of each share of Series A preferred stock is $2,500 (each share of Series A preferred stock is convertible into 1,000 shares of common stock). In addition, Ovid Therapeutics has granted the underwriters a 30-day option to purchase additional shares of common stock of up to 15% of the aggregate number of shares offered in the common stock offering. The Offerings are expected to close on October 8, 2019, subject to customary closing conditions. As described above, each share of Series A preferred stock is convertible into 1,000 shares of common stock, provided that conversion will be prohibited, subject to certain exceptions, if, as a result, the holder and its affiliates would beneficially own more than, at the written election of the holder, either 9.99% or 14.99% of the total number of shares of our common stock then issued and outstanding. In addition, upon written notice to Ovid Therapeutics, the holders may elect to increase or decrease such percentage limitation to any other number less than or equal to 19.99%.Cowen and William Blair are acting as joint book-running managers for the Offerings. JMP Securities and Ladenburg Thalmann are acting as co-managers for the Offerings.Ovid Therapeutics expects to receive combined gross proceeds of $32.5 million from the Offerings, before deducting underwriting discounts and offering expenses. Ovid Therapeutics intends to use the net proceeds from the Offerings primarily to advance the clinical development of its OV101 and OV935 programs and the remainder of the net proceeds for working capital and general corporate purposes.The securities described above are being offered by Ovid Therapeutics pursuant to an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission (“SEC”) dated June 19, 2018. A preliminary prospectus supplement relating to each of the Offerings has been, and a final prospectus supplement related to each of the Offerings will be, filed with the SEC and will be available on the SEC's website at http://www.sec.gov. Copies of the preliminary and final prospectus supplements relating to the Offerings may be obtained, when available, by contacting Cowen at c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York, 11717, Attention: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297-2926; or William Blair at 150 North Riverside Plaza, Chicago, Illinois 60606, Attention: Prospectus Department, by telephone at 800-621-0687 or by email at prospectus@williamblair.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.About Ovid Therapeutics Inc. Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. Ovid’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE).Forward-Looking Information is Subject to Risk and UncertaintyInvestors are cautioned that statements in this press release, including regarding expectations as to the size, completion, timing and use of proceeds relating to the proposed Offerings, constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the proposed public offering. Words such as "may," “intend,” “will,” “potential,” and similar expressions are intended to identify forward-looking statements.  These forward-looking statements are based upon Ovid’s current expectations. Ovid’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to market conditions and the satisfaction of customary closing conditions related to the proposed Offerings. These and other risks facing Ovid can be found under the heading "Risk Factors" in Ovid’s periodic reports, including its quarterly report on Form 10-Q for the quarter ended June 30, 2019 and other filings with the SEC. There can be no assurance that Ovid will be able to complete the proposed Offerings. Ovid expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.ContactsInvestors and Media: Ovid Therapeutics Inc. Investor Relations & Public Relations irpr@ovidrx.comOrInvestors: Steve Klass Burns McClellan, Inc. sklass@burnsmc.com (212) 213-0006Media: Katie Engleman 1AB katie@1abmedia.com (919) 333-7722

  • Benzinga

    The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week lows on Oct. 3) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed on Thursday) ...

  • GlobeNewswire

    Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases, today announced that it intends to offer and sell shares of its common stock and Series A convertible preferred stock (the “Series A preferred stock”) in two concurrent but separate underwritten public offerings. Neither of the proposed common stock offering or the Series A preferred stock offering (together, the “Offerings”) are contingent upon the consummation of the other. Cowen and William Blair are acting as joint book-running managers for the Offerings.

  • GlobeNewswire

    Ovid Therapeutics Announces Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare Epilepsies

    Ovid Therapeutics Inc. (OVID) today announced positive initial data from the ENDYMION trial, a Phase 2 open-label extension study of soticlestat (OV935/TAK935) in patients with rare developmental and epileptic encephalopathies (DEE). Soticlestat is a potent, highly-selective first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H) being investigated as a novel approach to treating adults and children with rare epilepsies in collaboration with Takeda Pharmaceutical Company Limited.

  • Could The Ovid Therapeutics Inc. (NASDAQ:OVID) Ownership Structure Tell Us Something Useful?
    Simply Wall St.

    Could The Ovid Therapeutics Inc. (NASDAQ:OVID) Ownership Structure Tell Us Something Useful?

    The big shareholder groups in Ovid Therapeutics Inc. (NASDAQ:OVID) have power over the company. Generally speaking, as...

  • GlobeNewswire

    Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 NEPTUNE Trial of OV101 for the Treatment of Angelman Syndrome

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the first patient has been randomized in the company’s single, pivotal Phase 3 NEPTUNE clinical trial evaluating OV101 (gaboxadol), a novel delta (δ)-selective GABAA receptor agonist, in Angelman syndrome. “There are currently no other therapies in clinical development for Angelman syndrome and no approved treatments for this disorder exist today,” said Amit Rakhit, MD, MBA, Chief Medical Officer and Head of Research & Development at Ovid.

  • GlobeNewswire

    Ovid Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    NEW YORK, Sept. 09, 2019 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare.

  • GlobeNewswire

    Ovid Therapeutics Announces Participation in Two Upcoming Investor Conferences

    Members of the Company’s management team will participate in one-on-one meetings with investors on Thursday, September 5, 2019. The conference will be held at the Four Seasons Hotel in Boston, MA. Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer of Ovid, will present a corporate overview on Tuesday, September 24, 2019 at 9:00 a.m. EDT.  Ovid will also participate in one-on-one meetings with investors.

  • GlobeNewswire

    Ovid Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Recent Progress

    Phase 3 NEPTUNE Trial of OV101 in Angelman Syndrome on Track to Enroll the First Patients in the Third Quarter of 2019 Regulatory Authorities in the U.S. and Germany agree.

  • Some Ovid Therapeutics (NASDAQ:OVID) Shareholders Have Taken A Painful 71% Share Price Drop
    Simply Wall St.

    Some Ovid Therapeutics (NASDAQ:OVID) Shareholders Have Taken A Painful 71% Share Price Drop

    Over the last month the Ovid Therapeutics Inc. (NASDAQ:OVID) has been much stronger than before, rebounding by 69...

  • GlobeNewswire

    Ovid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman Syndrome

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the European Commission (EC) has granted orphan drug designation (ODD) to OV101 (gaboxadol) for the treatment of Angelman syndrome based on the results of the Phase 2 STARS trial. OV101 is believed to be the only delta (δ)-selective GABAA receptor agonist in clinical development for the treatment of certain neurodevelopmental disorders, including Angelman syndrome. “We are proud to be granted Orphan Drug Designation by the European Commission.

  • GlobeNewswire

    Ovid Therapeutics Initiates Pivotal Phase 3 Clinical Trial in Angelman Syndrome; Multiple Data Readouts Across Rare Neurological Disease Pipeline Expected in 2H 2019 and Early 2020

    Ovid Therapeutics Inc. (OVID), today announced that following a Type C Meeting with the U.S. Food and Drug Administration (FDA), it has initiated the pivotal Phase 3 NEPTUNE trial with OV101, a novel delta (δ)-selective GABAA receptor agonist, in Angelman syndrome. Ovid plans to enroll the first patients in NEPTUNE during the third quarter of 2019 and anticipates topline data from the trial to be available by mid-2020. The results of the trial, if positive, are intended to support a New Drug Application for OV101 for the treatment of Angelman syndrome.

  • GlobeNewswire

    Ovid Therapeutics to Host R&D Day on June 27, 2019

    NEW YORK, June 18, 2019 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare.

  • Ovid Therapeutics to Present at the 12th International Epilepsy Colloquium
    PR Newswire

    Ovid Therapeutics to Present at the 12th International Epilepsy Colloquium

    NEW YORK, May 23, 2019 /PRNewswire/ -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, will present data on safety, tolerability, exploratory and secondary outcomes from the Phase 1b/2a clinical trial of OV935/TAK-935 in adult patients with developmental and epileptic encephalopathies (DEE). The data will be presented as a poster at the 12th International Epilepsy Colloquium (IEC), taking place May 26-28 in Lyon, France.

  • GlobeNewswire

    Ovid Therapeutics Reports First Quarter 2019 Financial Results

    Remains on track for all previously stated milestones expected throughout 2019 The STARS study selected as one of three abstracts featured at the 2019 AAN Top Science Press.

  • Benzinga

    Ovid Therapeutics Rallies On Rare Genetic Disorder Drug Data

    Ovid Therapeutics Inc (NASDAQ: OVID ) shares have been on a steady downtrend since Aug. 6, 2018, when it released topline data from a Phase 2 study dubbed STARS that evaluated its OV101 for treating a ...

  • Have Insiders Been Buying Ovid Therapeutics Inc. (NASDAQ:OVID) Shares This Year?
    Simply Wall St.

    Have Insiders Been Buying Ovid Therapeutics Inc. (NASDAQ:OVID) Shares This Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares...

  • GlobeNewswire

    Ovid Therapeutics to Present at the American Academy of Neurology 71st Annual Meeting

    Ovid Therapeutics Inc. (OVID) continues to build on its neuroscience research platform with the presentation of data from the OV101 (gaboxadol) investigational program for rare neurodevelopmental conditions.  Ovid’s presentations on Angelman syndrome and Fragile X syndrome are part of the program at the 71st annual meeting of the American Academy of Neurology (AAN) in Philadelphia (May 4 - 10). “Ovid’s research efforts are focused on finding treatments for rare diseases, which are defined in the US as conditions affecting fewer than 200,000 people, and specifically, we seek to improve the lives of the approximately 8 million people in the US alone living with neurologic manifestations of rare diseases1,” said Amit Rakhit, MD, MBA, Chief Medical Officer and Head of Research & Development at Ovid.

  • GlobeNewswire

    Ovid Therapeutics Announces Senior Management Changes to Align Expertise with Advancing Clinical Stage Pipeline

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced changes to its senior management team to focus the company’s resources and attention on its late stage pipeline. Amit Rakhit, M.D., MBA, is adding the role of Head of R&D to his current position as Chief Medical Officer. As part of this transition, Dr. During has decided not to stand for reelection following his current term on Ovid’s Board of Directors.

  • GlobeNewswire

    Ovid Therapeutics Announces Appointment of Pharmaceutical Veteran, Thomas Perone, as Senior Vice President, General Counsel and Corporate Secretary

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced the appointment of Thomas Perone, as Senior Vice President, General Counsel and Corporate Secretary. Mr. Perone is succeeding Ana Ward who will be leaving the Company. “We are delighted to welcome Tom to Ovid,” said Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer of Ovid Therapeutics.